REG - Kanabo Group PLC - Submission for Bioavailability and Efficacy Trial

KanaboAnnouncement

07/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211207:nRSG7528Ua&default-theme=true

RNS Number : 7528U  Kanabo Group PLC  07 December 2021

Kanabo Group Plc

("Kanabo" or the "Company")

Submission for Medical Bioavailability and Efficacy Trial

Bioavailability and Efficacy Trial to Commence using VapePod

Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that
focuses on the distribution of cannabis-derived products for medical patients
and wellness CBD consumers, announces it has applied to undertake a
bioavailability and efficacy trial (the "Trial") of its proprietary Cannabis
inhalation formulas used in conjunction with its VapePod delivery device.

 

The outcome of this 3-month trial will be:

 

1. An approval to sell the medical vape and formulas in Israel - this will be
the first cannabis vape cartridges in the Israeli market.

 

2. To support sales in UK and Germany by providing physicians and the medical
establishments with evidence-based medicine.

 

3. This is expected to be the first clinical trial for a cannabis vape pen in
the world, that will provide bioavailability and efficacy data.

 

Kanabo, in partnership with Seach Medical Group, has submitted a clinical
trial protocol for approval at the Hadassah Medical Centre and subsequent
review by the Helsinki Committee to test the impact from the inhalation of
various Cannabis formulas via its proprietary VapePod delivery device, which
dispenses standardised and metered inhalations, on healthy volunteers.

 

As part of the Trial, participants will undertake a pharmacokinetic ("PK")
analysis to define THC and CBD Absorption, Distribution, Metabolism and
Excretion ("ADME") following the administration of the Company's proprietary
VapePod Formulas.

 

Once successfully completed, the Trial will help Kanabo target the rapidly
growing segments of the medicinal Cannabis market for patients who wish to
manage their pain using a clean and measurable method of treatment.

 

 

Avihu Tamir, Kanabo's CEO commented: "This is a ground-breaking trial which
will evaluate the bioavailability and efficacy of Cannabis-based inhalation
formulas administered via Kanabo's VapePod medical device. It is an important
milestone as it will help us with our ongoing efforts to allow specialist
consultants to prescribe a metered dose of medicinal cannabis that is
healthier for patients than the alternative which is typically smoking."

 

 

 

For further information, please visit http://www.kanabogroup.com/ or contact
the following:

 Kanabo Group Plc
 Avihu Tamir, CEO                                       Via Vox Markets
 Peterhouse Capital Ltd
 Eran Zucker (Financial Adviser)                        Tel: +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow (Corporate Broker)  Tel: +44 (0)20 7469 0930
 Vox Markets (Investor Relations)
 Kat Perez                                              KanaboGroup@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is an R&D company currently selling a range of wellness
CBD Products in the Primary Markets and Medical Cannabis Products. The
company's core strategy is to increase revenues from the sale of its Retail
CBD Products in the wellness sector and to grow the Kanabo brand through its
marketing initiatives.

About Seach Medical Group

 

The Seach Medical Group is a pioneer in the field of medical cannabis in
Israel since 2008. Seach now has experience, gained over the past decade, with
a global network of strategic partnerships and clinical trials.

 

About Hadassah University Medical Centre

 

The Trial will be conducted at the Hadassah University Medical Centre
("Hadassah"). Hadassah was first established in 1918 as a gift from the
Rothschild family, which has now expanded to include two University Hospitals
with over 1,000 beds, thirty-one operating theatres, nine intensive care units
and five schools of allied medial professions. Hadassah's physicians and
scientists are regularly engaged in a wide variety of clinical research
projects and trials.

 

About the Helsinki Committee

 

The Helsinki Committee's work is to authorise medical research and trials on
humans, which aim to expand medical knowledge and improve the outcomes of
medical treatment.

 

The work of the Helsinki Committee on this submission will ensure the
integrity of the Trail and ensure it is carried out in accordance with the
approved medical ethics guidelines outlined in the Declaration of Helsinki and
the various international conventions concerning medical experiments on
humans, and in accordance with the guidelines, laws and regulations which were
legislated by the Israeli parliament and the Ministry of Health with the aim
of regulating the issue of medical trials on humans.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFQLLBFLLLFBD